Goodwin Procter partner Jonathan Shapiro has entered an appearance for Caribou Biosciences Inc. and certain executives in a pending securities class action related to the company’s development of cell therapies for the treatment of certain forms of cancer. The case, filed Feb. 10 in California Northern District Court by Pomerantz LLP, contends that the defendants overstated the clinical and commercial viability of Caribou’s CB-010, a therapy intended to curtail tumor activity. The case, assigned to U.S. District Judge Vince Chhabria, is 3:23-cv-00609, Greenhalgh v. Caribou Biosciences, Inc. et al.
This suit was surfaced by Law.com Radar, a source for high-speed legal news and litigation updates personalized to your practice. Law.com Radar publishes daily updates on just-filed federal cases like this one. Click here to get started and be first to know about new suits in your region, practice area or client sector.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
